Fenretinide differentially modulates the levels of long- and very long-chain ceramides by downregulating Cers5 enzyme: evidence from bench to bedside

. 2017 Oct ; 95 (10) : 1053-1064. [epub] 20170710

Jazyk angličtina Země Německo Médium print-electronic

Typ dokumentu klinické zkoušky, časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/pmid28695226
Odkazy

PubMed 28695226
DOI 10.1007/s00109-017-1564-y
PII: 10.1007/s00109-017-1564-y
Knihovny.cz E-zdroje

UNLABELLED: Cystic fibrosis is the most common genetic disease, in which symptoms may be alleviated but not fully eliminated. Ceramides have long been implicated in the inflammatory etiology of cystic fibrosis, with contradicting reports with regards to their role. Recently, significant biological and biophysical differences have been observed between long- and very long-chain ceramides. This work reveals that long-chain ceramides are upregulated whereas very long-chain ceramides are downregulated in cell lines, mouse animal model, and patients with cystic fibrosis, compared with their controls. Treatment with fenretinide decreases the levels of long-chain ceramides and increases the levels of very long-chain ceramides. Our results show that restoration of cystic fibrosis conductance regulator (CFTR) expression is associated with normalization of aberrant levels of specific ceramides. This demonstrates for the first time a correlation between CFTR protein expression and regulation of specific ceramide levels. Furthermore, using cystic fibrosis lung epithelial cell lines, we demonstrate that this effect can be attributed to the transcriptional downregulation of ceramide synthase 5 (Cers5) enzyme. We also discovered a partial synergism between fenretinide and zinc (Zn2+), which deficiency has been reported in patients with cystic fibrosis. Overall, in addition to having direct translational application, we believe that our findings contribute to the understanding of ceramide metabolism in cystic fibrosis, as well as other inflammatory diseases where imbalances of ceramides have also been observed. KEY MESSAGES: Long- and very long-chain ceramides (LCCs and VLCCs) are biochemically distinct. LCCs are upregulated whereas VLCCs are downregulated in cystic fibrosis. Fenretinide downregulates the levels of LCCs and upregulates the levels of VLCCs. Fenretinide changes the balance of LCCs and VLCCs by downregulating Cers5 enzyme. Fenretinide and zinc ions cooperate in the modulation of ceramide levels.

Zobrazit více v PubMed

J Cell Physiol. 2004 Aug;200(2):235-44 PubMed

Nat Rev Genet. 2015 Jan;16(1):45-56 PubMed

Pediatr Pulmonol. 2008 Mar;43(3):281-7 PubMed

Am J Respir Cell Mol Biol. 2009 Jul;41(1):100-6 PubMed

Int J Biochem Cell Biol. 2012 Apr;44(4):620-8 PubMed

Transl Res. 2016 Feb;168:40-49 PubMed

Am J Respir Cell Mol Biol. 2008 Jan;38(1):47-56 PubMed

Otolaryngol Head Neck Surg. 2005 Nov;133(5):695-701 PubMed

J Nutr. 2003 Oct;133(10 ):3058-64 PubMed

Nat Med. 2003 Mar;9(3):322-30 PubMed

Nat Med. 2008 Apr;14(4):382-91 PubMed

J Lipid Res. 2012 Dec;53(12):2755-66 PubMed

Clin Transl Oncol. 2009 Apr;11(4):243-9 PubMed

Am J Physiol Lung Cell Mol Physiol. 2008 Aug;295(2):L303-13 PubMed

Prog Lipid Res. 2012 Jan;51(1):50-62 PubMed

J Biol Chem. 2012 Jun 15;287(25):21025-33 PubMed

Pediatr Res. 2014 Jun;75(6):762-6 PubMed

J Physiol. 2005 Dec 1;569(Pt 2):601-15 PubMed

J Biol Chem. 2001 Jun 8;276(23):20589-96 PubMed

Am J Respir Cell Mol Biol. 1993 May;8(5):522-9 PubMed

Drug Des Devel Ther. 2016 Nov 01;10 :3591-3597 PubMed

Histochem Cell Biol. 2013 Nov;140(5):533-47 PubMed

IUBMB Life. 2010 May;62(5):347-56 PubMed

Biochim Biophys Acta. 2005 Dec 30;1746(3):284-94 PubMed

Trends Mol Med. 2012 May;18(5):283-91 PubMed

J Lab Clin Med. 1957 Jul;50(1):152-7 PubMed

Ann Nutr Metab. 2008;52(2):152-6 PubMed

Mol Med. 2015 Apr 21;21:257-75 PubMed

Biometals. 2001 Sep-Dec;14(3-4):367-83 PubMed

Am J Respir Crit Care Med. 2010 Aug 1;182(3):369-75 PubMed

EMBO Mol Med. 2014 Aug 01;6(9):1205-14 PubMed

Nat Med. 2002 Jun;8(6):588-93 PubMed

Nat Med. 2010 Mar;16(3):313-8 PubMed

J Invest Dermatol. 2012 Feb;132(2):476-9 PubMed

Anal Biochem. 2013 Oct 15;441(2):182-4 PubMed

J Immunol. 2004 Jan 1;172(1):418-25 PubMed

J Biol Chem. 2001 Jun 29;276(26):23954-61 PubMed

J Phys Chem B. 2014 Sep 4;118(35):10460-70 PubMed

J Biol Chem. 1957 May;226(1):497-509 PubMed

PLoS One. 2013 May 14;8(5):e62968 PubMed

N Engl J Med. 2007 Jun 14;356(24):2457-71 PubMed

Hum Mutat. 2011 Nov;32(11):1197-203 PubMed

J Nutr. 2004 Jul;134(7):1711-5 PubMed

J Invest Dermatol. 1991 Apr;96(4):523-6 PubMed

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...